- Went public, Sep 2025
- Raised $11M Initial Public Offering, Sep 2025
- Raised $15M Series D, Feb 2016
About
Regentis Biomaterials is a tissue-repair company developing and commercializing a hydrogel platform for the repair of damaged tissue. Its current efforts are focused on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue. The company's first commercial product is GelrinC, a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to articular knee cartilage. After standard microfracture, the hydrogel is injected as a liquid and conforms to the lesion's size, shape, and depth, with no cutting or press fitting required to fill the lesion. After brief exposure to UV light, the hydrogel becomes a semisolid implant tightly integrated with the surrounding tissue and bone with no fibrin glue necessary to secure it in place. The implant acts as a scaffold, gradually eroding over time as new cartilage takes its place. GelrinC is completely resorbed in vivo within 6 to 12 months. The manufacturing process of GelrinC meets strict international safety, quality, and biocompatibility standards, including GMP and ISO 13485.
Funding history · 4 rounds · $43.5M total
Q&A
- What is Regentis Biomaterials' primary focus?
- Regentis Biomaterials is a tissue-repair company that develops and commercializes a hydrogel platform for repairing damaged tissue, with a current focus on orthopedic treatments using degradable hydrogel implants.
- What is Regentis Biomaterials' first commercial product?
- Regentis Biomaterials' first commercial product is GelrinC, a cell-free, off-the-shelf hydrogel implant designed for treating painful injuries to articular knee cartilage.
- When was Regentis Biomaterials founded?
- Regentis Biomaterials was founded in September 2004.
- What is the current employee count for Regentis Biomaterials?
- Regentis Biomaterials has 1-10 employees.
- What is the total amount of funding raised by Regentis Biomaterials to date?
- Regentis Biomaterials has raised a total of $43,500,000 USD.
- When did Regentis Biomaterials conduct its Series D funding round?
- Regentis Biomaterials conducted its Series D funding round in February 2016, with participation from General Oriental Investments and Haisco.
- When did Regentis Biomaterials go public?
- Regentis Biomaterials went public on NASDAQ in September 2025 through an Initial Public Offering that raised $11,000,000 USD.
- Who is a co-founder and CSO of Regentis Biomaterials?
- Prof. Dror Seliktar is a Co-Founder and CSO of Regentis Biomaterials.
Team · 2
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | regentis.co.il |
|---|---|
| linkedin.com/company/6144951 | |
| YouTube | youtube.com/channel/UCY231jR34KUS6RMeh6GbA0g |
Identifiers & details
| Legal name | Regentis Biomaterials |
|---|---|
| Founded | 2004-9 |
| Employees (exact) | 3 |
| Offices | Princeton; Mnster |
| Market cap | $34.9M |
| Status reason | Public on NASDAQ on Sep, 2025; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2025-09 | $11.0M |